Assessing reactivity to brain proteins beyond amyloid-beta and tau protein.
- Tau Protein IgG
- Amyloid-Beta Peptide IgG
- Rabaptin-5 + Presenilin IgG
- Alpha-Synuclein IgG
Measuring immune reactivity to factors involved in neuronal regeneration.
- Beta Nerve Growth Factor IgG
- Brain Derived Neurotrophic Factor IgG
- Neurotrophins IgG
- Somatotropin IgG
Enteric Nerve, Enzymes and Neurological Peptides
Assessing immune reactivity to the communication pathway between the gut and the brain.
- Enteric Nerve + Vasoactive Intestinal Peptide IgG
- Transglutaminases IgG
Assessing immune reactivity to pathogens known to cross-react with amyloid-beta.
- Oral Pathogens IgG
- Enterococcus faecalis IgG
- Escherichia coli CDT + Salmonella CDT IgG
- Campylobacter jejuni CDT IgG
- Herpes Type-1 IgG
Biomarkers for a collection of chemicals/heavy metals discovered to have associations to Alzheimer’s disease.
- Aluminums IgG
- Dinitrophenyl IgG
- Ethyl + Methyl Mercury IgG
- Phthalates IgG
Foods Cross-Reactive to Amyloid-Beta
8 out of 208 common foods, newly discovered to have a potential association with Alzheimer’s disease.
- Egg Yolk, raw + cooked IgG
- Lentil Lectin + Pea Lectin IgG
- Tuna, canned IgG
- Hazelnut Vicilin + Cashew Vicilin IgG
- Scallops + Squid IgG
- Caseins IgG
- Alpha-Gliadin + Gliadin Toxic Peptide IgG
- Non-Gluten Proteins IgG
Blood-Brain Barrier and Neurofilaments
Blood-Brain Barrier antibody biomarkers which assess the integrity of the blood-brain barrier.
- Blood-Brain Barrier Protein + Claudin-5 IgG
- Aquaporins IgG
- Neurofilaments Proteins IgG
- Identifying asymptomatic individuals at greater risk for developing cognitive decline including Alzheimer’s disease or other neurological disorders.
- Identifying reactivity to triggers of Alzheimer’s disease or other neurological disorders.
- Identifying the early stages of neurodegenerative processes.
- Monitoring the efficacy of lifestyle modifications for Alzheimer’s disease.
This Test Is Recommended for Patients Who:
- Are interested in preventing the development of Alzheimer’s disease, cognitive decline or other neurological disorder.
- Are exhibiting early signs of Alzheimer’s disease or other neurological disorder.
- Have been diagnosed with Alzheimer’s disease.
- Have a history of gastrointestinal disorders and/or diabetes.
- Played high-impact sports.
- Are immunoreactive against specific pathogens, chemicals and foods.
- Those currently undergoing a Bredesen Protocol programme.